ÂÜÀòÂÒÂ×

Matthew Verosloff is a highly skilled scientist with extensive experience in synthetic biology and gene editing. Currently serving as a Senior Scientist I at Mammoth Biosciences since September 2024, Matthew focuses on developing genetic medicines through innovative CRISPR applications. Previously, as a Scientist II at ReCode Therapeutics, Matthew led projects integrating gene editing with cutting-edge lipid nanoparticle technology. Earlier roles at Mammoth Biosciences involved harnessing Cas enzymes for novel assay development and employing high-throughput processes. A PhD holder in Synthetic Biology from Northwestern University, Matthew's academic background includes significant research on RNA mechanisms and CRISPR systems, complemented by a Master's in Biotechnology from the University of Pennsylvania and a Bachelor's in Biology from Rutgers University.